Compare SRPT & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRPT | MRK |
|---|---|---|
| Founded | 1980 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 260.2B |
| IPO Year | 1997 | N/A |
| Metric | SRPT | MRK |
|---|---|---|
| Price | $21.54 | $100.27 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 29 | 15 |
| Target Price | $26.23 | ★ $109.13 |
| AVG Volume (30 Days) | 3.7M | ★ 15.8M |
| Earning Date | 11-03-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 3.39% |
| EPS Growth | N/A | ★ 58.08 |
| EPS | N/A | ★ 7.56 |
| Revenue | $2,413,715,000.00 | ★ $64,235,000,000.00 |
| Revenue This Year | $13.83 | $1.97 |
| Revenue Next Year | N/A | $4.96 |
| P/E Ratio | ★ N/A | $13.27 |
| Revenue Growth | ★ 47.15 | 1.68 |
| 52 Week Low | $10.42 | $73.31 |
| 52 Week High | $129.84 | $105.84 |
| Indicator | SRPT | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 55.25 | 59.78 |
| Support Level | $20.76 | $96.06 |
| Resistance Level | $22.85 | $99.85 |
| Average True Range (ATR) | 1.20 | 2.46 |
| MACD | 0.26 | -0.70 |
| Stochastic Oscillator | 74.47 | 43.03 |
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).